Notably, it was shown that MM cells enriched for E-selectin ligands recognized by the monoclonal antibody Heca452 (MMHeca452Enriched) were resistant to bortezomib treatment in vivo, and this resistance was reversed by a small glycomimetic molecule, GMI-1271, which inhibits E-selectin/E-selectin ligand interaction (Natoni et al., 2017). Here, SELE is linked to Miyoshi myopathy.